Molecular Biomarkers for the Evaluation of Colorectal Cancer

Antonia R. Sepulveda, Stanley R. Hamilton, Carmen J. Allegra, Wayne Grody, Allison M. Cushman-Vokoun, William K. Funkhouser, Scott E. Kopetz, Christopher Lieu, Noralane Morey Lindor, Bruce D. Minsky, Federico A. Monzon, Daniel J. Sargent, Veena M. Singh, Joseph Willis, Jennifer Clark, Carol Colasacco, R. Bryan Rumble, Robyn Temple-Smolkin, Christina B. Ventura, Jan A. Nowak

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

Original languageEnglish (US)
Pages (from-to)221-260
Number of pages40
JournalAmerican Journal of Clinical Pathology
Volume147
Issue number3
DOIs
StatePublished - Mar 1 2017

Fingerprint

Colorectal Neoplasms
Biomarkers
Epidermal Growth Factor Receptor
Guidelines
Molecular Pathology
Therapeutics
Monoclonal Antibodies
Drug Therapy
Mutation
Genes

Keywords

  • gastrointestinal
  • genetics
  • histology
  • Molecular diagnostics
  • oncology

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Sepulveda, A. R., Hamilton, S. R., Allegra, C. J., Grody, W., Cushman-Vokoun, A. M., Funkhouser, W. K., ... Nowak, J. A. (2017). Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology, 147(3), 221-260. https://doi.org/10.1093/ajcp/aqw209

Molecular Biomarkers for the Evaluation of Colorectal Cancer. / Sepulveda, Antonia R.; Hamilton, Stanley R.; Allegra, Carmen J.; Grody, Wayne; Cushman-Vokoun, Allison M.; Funkhouser, William K.; Kopetz, Scott E.; Lieu, Christopher; Lindor, Noralane Morey; Minsky, Bruce D.; Monzon, Federico A.; Sargent, Daniel J.; Singh, Veena M.; Willis, Joseph; Clark, Jennifer; Colasacco, Carol; Rumble, R. Bryan; Temple-Smolkin, Robyn; Ventura, Christina B.; Nowak, Jan A.

In: American Journal of Clinical Pathology, Vol. 147, No. 3, 01.03.2017, p. 221-260.

Research output: Contribution to journalArticle

Sepulveda, AR, Hamilton, SR, Allegra, CJ, Grody, W, Cushman-Vokoun, AM, Funkhouser, WK, Kopetz, SE, Lieu, C, Lindor, NM, Minsky, BD, Monzon, FA, Sargent, DJ, Singh, VM, Willis, J, Clark, J, Colasacco, C, Rumble, RB, Temple-Smolkin, R, Ventura, CB & Nowak, JA 2017, 'Molecular Biomarkers for the Evaluation of Colorectal Cancer', American Journal of Clinical Pathology, vol. 147, no. 3, pp. 221-260. https://doi.org/10.1093/ajcp/aqw209
Sepulveda AR, Hamilton SR, Allegra CJ, Grody W, Cushman-Vokoun AM, Funkhouser WK et al. Molecular Biomarkers for the Evaluation of Colorectal Cancer. American Journal of Clinical Pathology. 2017 Mar 1;147(3):221-260. https://doi.org/10.1093/ajcp/aqw209
Sepulveda, Antonia R. ; Hamilton, Stanley R. ; Allegra, Carmen J. ; Grody, Wayne ; Cushman-Vokoun, Allison M. ; Funkhouser, William K. ; Kopetz, Scott E. ; Lieu, Christopher ; Lindor, Noralane Morey ; Minsky, Bruce D. ; Monzon, Federico A. ; Sargent, Daniel J. ; Singh, Veena M. ; Willis, Joseph ; Clark, Jennifer ; Colasacco, Carol ; Rumble, R. Bryan ; Temple-Smolkin, Robyn ; Ventura, Christina B. ; Nowak, Jan A. / Molecular Biomarkers for the Evaluation of Colorectal Cancer. In: American Journal of Clinical Pathology. 2017 ; Vol. 147, No. 3. pp. 221-260.
@article{8b58a41527514c3f8c75a1c7a3aebf0f,
title = "Molecular Biomarkers for the Evaluation of Colorectal Cancer",
abstract = "Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.",
keywords = "gastrointestinal, genetics, histology, Molecular diagnostics, oncology",
author = "Sepulveda, {Antonia R.} and Hamilton, {Stanley R.} and Allegra, {Carmen J.} and Wayne Grody and Cushman-Vokoun, {Allison M.} and Funkhouser, {William K.} and Kopetz, {Scott E.} and Christopher Lieu and Lindor, {Noralane Morey} and Minsky, {Bruce D.} and Monzon, {Federico A.} and Sargent, {Daniel J.} and Singh, {Veena M.} and Joseph Willis and Jennifer Clark and Carol Colasacco and Rumble, {R. Bryan} and Robyn Temple-Smolkin and Ventura, {Christina B.} and Nowak, {Jan A.}",
year = "2017",
month = "3",
day = "1",
doi = "10.1093/ajcp/aqw209",
language = "English (US)",
volume = "147",
pages = "221--260",
journal = "American Journal of Clinical Pathology",
issn = "0002-9173",
publisher = "American Society of Clinical Pathologists",
number = "3",

}

TY - JOUR

T1 - Molecular Biomarkers for the Evaluation of Colorectal Cancer

AU - Sepulveda, Antonia R.

AU - Hamilton, Stanley R.

AU - Allegra, Carmen J.

AU - Grody, Wayne

AU - Cushman-Vokoun, Allison M.

AU - Funkhouser, William K.

AU - Kopetz, Scott E.

AU - Lieu, Christopher

AU - Lindor, Noralane Morey

AU - Minsky, Bruce D.

AU - Monzon, Federico A.

AU - Sargent, Daniel J.

AU - Singh, Veena M.

AU - Willis, Joseph

AU - Clark, Jennifer

AU - Colasacco, Carol

AU - Rumble, R. Bryan

AU - Temple-Smolkin, Robyn

AU - Ventura, Christina B.

AU - Nowak, Jan A.

PY - 2017/3/1

Y1 - 2017/3/1

N2 - Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

AB - Objectives: To develop evidence-based guideline recommendations through a systematic review of the literature to establish standard molecular biomarker testing of colorectal cancer (CRC) tissues to guide epidermal growth factor receptor (EGFR) therapies and conventional chemotherapy regimens. Methods: The American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and American Society of Clinical Oncology convened an expert panel to develop an evidence-based guideline to establish standard molecular biomarker testing and guide therapies for patients with CRC. A comprehensive literature search that included more than 4,000 articles was conducted. Results: Twenty-one guideline statements were established. Conclusions: Evidence supports mutational testing for EGFR signaling pathway genes, since they provide clinically actionable information as negative predictors of benefit to anti-EGFR monoclonal antibody therapies for targeted therapy of CRC. Mutations in several of the biomarkers have clear prognostic value. Laboratory approaches to operationalize CRC molecular testing are presented.

KW - gastrointestinal

KW - genetics

KW - histology

KW - Molecular diagnostics

KW - oncology

UR - http://www.scopus.com/inward/record.url?scp=85022340089&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85022340089&partnerID=8YFLogxK

U2 - 10.1093/ajcp/aqw209

DO - 10.1093/ajcp/aqw209

M3 - Article

AN - SCOPUS:85022340089

VL - 147

SP - 221

EP - 260

JO - American Journal of Clinical Pathology

JF - American Journal of Clinical Pathology

SN - 0002-9173

IS - 3

ER -